AUTHOR=Chen Guanglei , Jin Yaxian , Chu Cancan , Zheng Yuhao , Chen Yunzhi , Zhu Xing 

TITLE=Genetic prediction of blood metabolites mediating the relationship between gut microbiota and Alzheimer’s disease: a Mendelian randomization study

JOURNAL=Frontiers in Microbiology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1414977

DOI=10.3389/fmicb.2024.1414977

ISSN=1664-302X

ABSTRACT=<sec id="sec1"><title>Background</title><p>Observational studies have suggested an association between gut microbiota and Alzheimer’s disease (AD); however, the causal relationship remains unclear, and the role of blood metabolites in this association remains elusive.</p></sec><sec id="sec2"><title>Purpose</title><p>To elucidate the causal relationship between gut microbiota and AD and to investigate whether blood metabolites serve as potential mediators.</p></sec><sec id="sec3"><title>Materials and methods</title><p>Univariable Mendelian randomization (UVMR) analysis was employed to assess the causal relationship between gut microbiota and AD, while multivariable MR (MVMR) was utilized to mitigate confounding factors. Subsequently, a two-step mediation MR approach was employed to explore the role of blood metabolites as potential mediators. We primarily utilized the inverse variance-weighted method to evaluate the causal relationship between exposure and outcome, and sensitivity analyses including Contamination mixture, Maximum-likelihood, Debiased inverse-variance weighted, MR-Egger, Bayesian Weighted Mendelian randomization, and MR pleiotropy residual sum and outlier were conducted to address pleiotropy.</p></sec><sec id="sec4"><title>Results</title><p>After adjustment for reverse causality and MVMR correction, class Actinobacteria (OR: 1.03, 95% CI: 1.01–1.06, <italic>p</italic> = 0.006), family Lactobacillaceae (OR: 1.03, 95% CI: 1.00–1.05, <italic>p</italic> = 0.017), genus <italic>Lachnoclostridium</italic> (OR: 1.03, 95% CI: 1.00–1.06, <italic>p</italic> = 0.019), genus <italic>Ruminiclostridium9</italic> (OR: 0.97, 95% CI: 0.94–1.00, <italic>p</italic> = 0.027) and genus <italic>Ruminiclostridium6</italic> (OR: 1.03, 95% CI: 1.01–1.05, <italic>p</italic> = 0.009) exhibited causal effects on AD. Moreover, 1-ribosyl-imidazoleacetate levels (−6.62%), Metabolonic lactone sulfate levels (2.90%), and Nonadecanoate (19:0) levels (−12.17%) mediated the total genetic predictive effects of class Actinobacteria on AD risk. Similarly, 2-stearoyl-GPE (18:0) levels (−9.87%), Octadecanedioylcarnitine (C18-DC) levels (4.44%), 1-(1-enyl-stearoyl)-2-oleoyl-GPE (p-18:0/18:1) levels (38.66%), and X-23639 levels (13.28%) respectively mediated the total genetic predictive effects of family Lactobacillaceae on AD risk. Furthermore, Hexadecanedioate (C16-DC) levels (5.45%) mediated the total genetic predictive effects of genus <italic>Ruminiclostridium 6</italic> on AD risk; Indole-3-carboxylate levels (13.91%), X-13431 levels (7.08%), Alpha-ketoglutarate to succinate ratio (−13.91%), 3-phosphoglycerate to glycerate ratio (15.27%), and Succinate to proline ratio (−14.64%) respectively mediated the total genetic predictive effects of genus <italic>Ruminiclostridium 9</italic> on AD risk.</p></sec><sec id="sec5"><title>Conclusion</title><p>Our mediation MR analysis provides genetic evidence suggesting the potential mediating role of blood metabolites in the causal relationship between gut microbiota and AD. Further large-scale randomized controlled trials are warranted to validate the role of blood metabolites in the specific mechanisms by which gut microbiota influence AD.</p></sec>